Macrophages and renal fibrosis

Seminars in Nephrology

Volumn 30, Issue 3, 2010, Pages 302-317

  Vernon, Madeleine A ^a   Mylonas, Katie J ^a   Hughes, Jeremy ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Extracellular matrix; Fibroblast; Fibrosis; Macrophage; Myofibroblast

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; DOXORUBICIN; GALECTIN 3; GROWTH FACTOR; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; OSTEOPONTIN; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; DIABETIC NEPHROPATHY; DISEASE COURSE; FIBROBLAST; GLOMERULONEPHRITIS; HUMAN; IN VIVO STUDY; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY SCAR; LEUKOCYTE; MACROPHAGE; MEDIATOR; MONOCYTE; MYOFIBROBLAST; NEPHROTOXICITY; NONHUMAN; PERICYTE; PHENOTYPE; PRIORITY JOURNAL; REPERFUSION INJURY; URETER OBSTRUCTION;

ANIMALS; FIBROSIS; HUMANS; KIDNEY; KIDNEY DISEASES; MACROPHAGE ACTIVATION; MACROPHAGES; MONOCYTES;

EID: 77953895145     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.03.004     Document Type: Article

References (126)

1. Hunter M.G., Hurwitz S., Bellamy C.O., Duffield J.S. Quantitative morphometry of lupus nephritis: the significance of collagen, tubular space, and inflammatory infiltrate. Kidney Int 2005, 67:94-102.
2. Dufour J.F., DeLellis R., Kaplan M.M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 1997, 127:981-985.
3. Duffield J.S., Forbes S.J., Constandinou C.M., Clay S., Partolina M., Vuthoori S., et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005, 115:56-65.
4. Gremizzi C., Vergani A., Paloschi V., Secchi A. Impact of pancreas transplantation on type 1 diabetes-related complications. Curr Opin Organ Transplant 2010, 15:119-123.
5. Jefferson J.A., Johnson R.J. Experimental mesangial proliferative glomerulonephritis (the anti-Thy-1.1 model). J Nephrol 1999, 12:297-307.
6. Cochrane A.L., Kett M.M., Samuel C.S., Campanale N.V., Anderson W.P., Hume D.A., et al. Renal structural and functional repair in a mouse model of reversal of ureteral obstruction. J Am Soc Nephrol 2005, 16:3623-3630.
7. Eardley K.S., Cockwell P. Macrophages and progressive tubulointerstitial disease. Kidney Int 2005, 68:437-455.
8. Hume D.A. The mononuclear phagocyte system. Curr Opin Immunol 2006, 18:49-53.
9. Gordon S. The macrophage: past, present and future. Eur J Immunol 2007, 37(Suppl 1):S9-S17.
10. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
11. Yonemoto S., Machiguchi T., Nomura K., Minakata T., Nanno M., Yoshida H. Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus. Clin Exp Nephrol 2006, 10:186-192.
12. Yoshimoto K., Wada T., Furuichi K., Sakai N., Iwata Y., Yokoyama H. CD68 and MCP-1/CCR2 expression of initial biopsies reflect the outcomes of membranous nephropathy. Nephron Clin Pract 2004, 98:c25-c34.
13. Eardley K.S., Kubal C., Zehnder D., Quinkler M., Lepenies J., Savage C.O., et al. The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. Kidney Int 2008, 74:495-504.
14. Eardley K.S., Zehnder D., Quinkler M., Lepenies J., Bates R.L., Savage C.O., et al. The relationship between albuminuria, MCP-1/CCL2, and interstitial macrophages in chronic kidney disease. Kidney Int 2006, 69:1189-1197.
15. Brosius F.C., Alpers C.E., Bottinger E.P., Breyer M.D., Coffman T.M., Gurley S.B., et al. Mouse models of diabetic nephropathy. J Am Soc Nephrol 2009, 20:2503-2512.
16. Wilson H.M., Chettibi S., Jobin C., Walbaum D., Rees A.J., Kluth D.C. Inhibition of macrophage nuclear factor-kappaB leads to a dominant anti-inflammatory phenotype that attenuates glomerular inflammation in vivo. Am J Pathol 2005, 167:27-37.
17. Wang Y., Wang Y.P., Tay Y.C., Harris D.C. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000, 58:1797-1804.
18. Chevalier R.L., Forbes M.S., Thornhill B.A. Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009, 75:1145-1152.
19. Schlondorff D., Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009, 20:1179-1187.
20. Moura I.C., Benhamou M., Launay P., Vrtovsnik F., Blank U., Monteiro R.C. The glomerular response to IgA deposition in IgA nephropathy. Semin Nephrol 2008, 28:88-95.
21. Diamond J.R. Macrophages and progressive renal disease in experimental hydronephrosis. Am J Kidney Dis 1995, 26:133-140.
22. Fine L.G., Norman J.T. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008, 74:867-872.
23. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
24. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110:341-350.
25. Kuusniemi A.M., Lapatto R., Holmberg C., Karikoski R., Rapola J., Jalanko H. Kidneys with heavy proteinuria show fibrosis, inflammation, and oxidative stress, but no tubular phenotypic change. Kidney Int 2005, 68:121-132.
26. Zeisberg E.M., Potenta S.E., Sugimoto H., Zeisberg M., Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol 2008, 19:2282-2287.
27. Wada T., Sakai N., Matsushima K., Kaneko S. Fibrocytes: a new insight into kidney fibrosis. Kidney Int 2007, 72:269-273.
28. Sakai N., Furuichi K., Shinozaki Y., Yamauchi H., Toyama T., Kitajima S., et al. Fibrocytes are involved in the pathogenesis of human chronic kidney disease. Hum Pathol 2009, In press.
29. Sakai N., Wada T., Yokoyama H., Lipp M., Ueha S., Matsushima K., et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl Acad Sci U S A 2006, 103:14098-14103.
30. Lin S.L., Kisseleva T., Brenner D.A., Duffield J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173:1617-1627.
31. Lin S.L., Castano A.P., Nowlin B.T., Lupher M.L., Duffield J.S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009, 183:6733-6743.
32. Humphreys B.D., Lin S.L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97.
33. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994, 331:1286-1292.
34. Hugo C., Daniel C. Thrombospondin in renal disease. Nephron Exp Nephrol 2009, 111:e61-e66.
35. Sato M., Muragaki Y., Saika S., Roberts A.B., Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 2003, 112:1486-1494.
36. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000, 97:8015-8020.
37. Akagi Y., Isaka Y., Arai M., Kaneko T., Takenaka M., Moriyama T., et al. Inhibition of TGF-beta 1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996, 50:148-155.
38. Bottinger E.P., Letterio J.J., Roberts A.B. Biology of TGF-beta in knockout and transgenic mouse models. Kidney Int 1997, 51:1355-1360.
39. Wang W., Huang X.R., Li A.G., Liu F., Li J.H., Truong L.D., et al. Signaling mechanism of TGF-beta1 in prevention of renal inflammation: role of Smad7. J Am Soc Nephrol 2005, 16:1371-1383.
40. Qi W., Chen X., Polhill T.S., Sumual S., Twigg S., Gilbert R.E., et al. TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am J Physiol Renal Physiol 2006, 290:F703-F709.
41. Zeisberg M., Kalluri R. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008, 23:1395-1398.
42. Hruska K.A. Treatment of chronic tubulointerstitial disease: a new concept. Kidney Int 2002, 61:1911-1922.
43. Phanish M.K., Winn S.K., Dockrell M.E. Connective tissue growth factor-(CTGF, CCN2)-a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 2009, 114:e83-e92.
44. Floege J., Eitner F., Alpers C.E. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008, 19:12-23.
45. Johnson R.J., Raines E.W., Floege J., Yoshimura A., Pritzl P., Alpers C., et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992, 175:1413-1416.
46. Gilbert R.E., Kelly D.J., McKay T., Chadban S., Hill P.A., Cooper M.E., et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001, 59:1324-1332.
47. Mazzali M., Kipari T., Ophascharoensuk V., Wesson J.A., Johnson R., Hughes J. Osteopontin-a molecule for all seasons. QJM 2002, 95:3-13.
48. Nicholas S.B., Liu J., Kim J., Ren Y., Collins A.R., Nguyen L., et al. Critical role for osteopontin in diabetic nephropathy. Kidney Int 2009, 77:588-600.
49. Ophascharoensuk V., Giachelli C.M., Gordon K., Hughes J., Pichler R., Brown P., et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999, 56:571-580.
50. MacKinnon A.C., Farnworth S.L., Hodkinson P.S., Henderson N.C., Atkinson K.M., Leffler H., et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008, 180:2650-2658.
51. Henderson N.C., Mackinnon A.C., Farnworth S.L., Poirier F., Russo F.P., Iredale J.P., et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006, 103:5060-5065.
52. Henderson N.C., Mackinnon A.C., Farnworth S.L., Kipari T., Haslett C., Iredale J.P., et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008, 172:288-298.
53. Mori R., Shaw T.J., Martin P. Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med 2008, 205:43-51.
54. Daley W.P., Peters S.B., Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci 2008, 121:255-264.
55. Lorand L., Conrad S.M. Transglutaminases. Mol Cell Biochem 1984, 58:9-35.
56. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69:562-573.
57. Ronco P., Lelongt B., Piedagnel R., Chatziantoniou C. Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin Nephrol 2007, 27:352-362.
58. Iimura O., Takahashi H., Yashiro T., Madoiwa S., Sakata Y., Asano Y., et al. Effect of ureteral obstruction on matrix metalloproteinase-2 in rat renal cortex. Clin Exp Nephrol 2004, 8:223-229.
59. Nishida M., Okumura Y., Ozawa S., Shiraishi I., Itoi T., Hamaoka K. MMP-2 inhibition reduces renal macrophage infiltration with increased fibrosis in UUO. Biochem Biophys Res Commun 2007, 354:133-139.
60. Tan T.K., Zheng G., Hsu T.T., Wang Y., Lee V.W., Tian X., et al. Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol 2010, 176:1256-1270.
61. Rodgers K.D., Rao V., Meehan D.T., Fager N., Gotwals P., Ryan S.T., et al. Monocytes may promote myofibroblast accumulation and apoptosis in Alport renal fibrosis. Kidney Int 2003, 63:1338-1355.
62. Kim H., Oda T., Lopez-Guisa J., Wing D., Edwards D.R., Soloway P.D., et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2001, 12:736-748.
63. Kassiri Z., Oudit G.Y., Kandalam V., Awad A., Wang X., Ziou X., et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 2009, 20:1223-1235.
64. Geissmann F., Jung S., Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003, 19:71-82.
65. Auffray C., Sieweke M.H., Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-692.
66. Rees A. Monocyte and macrophage biology: an overview. Semin Nephrol 2010, 30:216-233.
67. Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-661.
68. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., et al. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 2007, 317:666-670.
69. Williams T.M., Little M.H., Ricardo S.D. Macrophages in renal development, injury and repair. Semin Nephrol 2010, 30:255-267.
70. Li L., Okusa M.D. Macrophages, dendritic cells and kidney ischaemia-reperfusion injury. Semin Nephrol 2010, 72:268-277.
71. Tesch G.H. Macrophages and diabetic nephropathy. Semin Nephrol 2010, 30:290-301.
72. Duffield J.S. Macrophages and immunological inflammation of the kidney. Semin Nephrol 2010, 30:234-254.
73. Chadban S.J., Huiling W., Hughes J. Macrophages and kidney transplantation. Semin Nephrol 2010, 30:278-289.
74. Goerdt S., Politz O., Schledzewski K., Birk R., Gratchev A., Guillot P., et al. Alternative versus classical activation of macrophages. Pathobiology 1999, 67:222-226.
75. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003, 3:23-35.
76. Duffield J.S. The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond) 2003, 104:27-38.
77. Mylonas K.J., Nair M.G., Prieto-Lafuente L., Paape D., Allen J.E. Alternatively activated macrophages elicited by helminth infection can be reprogrammed to enable microbial killing. J Immunol 2009, 182:3084-3094.
78. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
79. Wynes M.W., Frankel S.K., Riches D.W. IL-4-induced macrophage-derived IGF-I protects myofibroblasts from apoptosis following growth factor withdrawal. J Leukoc Biol 2004, 76:1019-1027.
80. Song E., Ouyang N., Horbelt M., Antus B., Wang M., Exton M.S. Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts. Cell Immunol 2000, 204:19-28.
81. Gibbs D.F., Warner R.L., Weiss S.J., Johnson K.J., Varani J. Characterization of matrix metalloproteinases produced by rat alveolar macrophages. Am J Respir Cell Mol Biol 1999, 20:1136-1144.
82. Shipley J.M., Wesselschmidt R.L., Kobayashi D.K., Ley T.J., Shapiro S.D. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci U S A 1996, 93:3942-3946.
83. Zheng G., Lyons J.G., Tan T.K., Wang Y., Hsu T.T., Min D., et al. Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol 2009, 175:580-591.
84. Lange-Sperandio B., Trautmann A., Eickelberg O., Jayachandran A., Oberle S., Schmidutz F., et al. Leukocytes induce epithelial to mesenchymal transition after unilateral ureteral obstruction in neonatal mice. Am J Pathol 2007, 171:861-871.
85. Savill J., Dransfield I., Gregory C., Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002, 2:965-975.
86. Sindrilaru A., Peters T., Schymeinsky J., Oreshkova T., Wang H., Gompf A., et al. Wound healing defect of Vav3-/- mice due to impaired {beta}2-integrin-dependent macrophage phagocytosis of apoptotic neutrophils. Blood 2009, 113:5266-5276.
87. Fallowfield J.A., Mizuno M., Kendall T.J., Constandinou C.M., Benyon R.C., Duffield J.S., et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis. J Immunol 2007, 178:5288-5295.
88. Nacu N., Luzina I.G., Highsmith K., Lockatell V., Pochetuhen K., Cooper Z.A., et al. Macrophages produce TGF-beta-induced (beta-ig-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts. J Immunol 2008, 180:5036-5044.
89. Popov Y., Sverdlov D.Y., Bhaskar K.R., Sharma A.K., Millonig G., Patsenker E., et al. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am J Physiol Gastrointest Liver Physiol 2010, 298:G323-G334.
90. Duffield J.S., Erwig L.P., Wei X., Liew F.Y., Rees A.J., Savill J.S. Activated macrophages direct apoptosis and suppress mitosis of mesangial cells. J Immunol 2000, 164:2110-2119.
91. Duffield J.S., Ware C.F., Ryffel B., Savill J. Suppression by apoptotic cells defines tumor necrosis factor-mediated induction of glomerular mesangial cell apoptosis by activated macrophages. Am J Pathol 2001, 159:1397-1404.
92. Lobov I.B., Rao S., Carroll T.J., Vallance J.E., Ito M., Ondr J.K., et al. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Nature 2005, 437:417-421.
93. Lang R., Lustig M., Francois F., Sellinger M., Plesken H. Apoptosis during macrophage-dependent ocular tissue remodelling. Development 1994, 120:3395-3403.
94. Nishida M., Okumura Y., Fujimoto S., Shiraishi I., Itoi T., Hamaoka K. Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem Biophys Res Commun 2005, 332:11-16.
95. Nishida M., Fujinaka H., Matsusaka T., Price J., Kon V., Fogo A.B., et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest 2002, 110:1859-1868.
96. Swirski F.K., Nahrendorf M., Etzrodt M., Wildgruber M., Cortez-Retamozo V., Panizzi P., et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009, 325:612-616.
97. Castaño A., Lin S.-L., Surowy T., Nowlin B.T., Turlapati S.A., Patel T., et al. Serum amyloid P inhibits fibrosis through FcγR-dependent monocyte-macrophage regulation in vivo. Sci Transl Med 2009, 1:5-13.
98. Van Rooijen N., Sanders A. Kupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid. Hepatology 1996, 23:1239-1243.
99. Sung S.A., Jo S.K., Cho W.Y., Won N.H., Kim H.K. Reduction of renal fibrosis as a result of liposome encapsulated clodronate induced macrophage depletion after unilateral ureteral obstruction in rats. Nephron Exp Nephrol 2007, 105:e1-e9.
100. Kitamoto K., Machida Y., Uchida J., Izumi Y., Shiota M., Nakao T., et al. Effects of liposome clodronate on renal leukocyte populations and renal fibrosis in murine obstructive nephropathy. J Pharmacol Sci 2009, 111:285-292.
101. Ko G.J., Boo C.S., Jo S.K., Cho W.Y., Kim H.K. Macrophages contribute to the development of renal fibrosis following ischaemia/reperfusion-induced acute kidney injury. Nephrol Dial Transplant 2008, 23:842-852.
102. Cailhier J.F., Partolina M., Vuthoori S., Wu S., Ko K., Watson S., et al. Conditional macrophage ablation demonstrates that resident macrophages initiate acute peritoneal inflammation. J Immunol 2005, 174:2336-2342.
103. Duffield J.S., Tipping P.G., Kipari T., Cailhier J.F., Clay S., Lang R., et al. Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol 2005, 167:1207-1219.
104. Karlmark K.R., Weiskirchen R., Zimmermann H.W., Gassler N., Ginhoux F., Weber C., et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50:261-274.
105. McDonald J.R. Selective chemokine receptor-targeted depletion of pathological cells as a therapeutic strategy for inflammatory, allergic and autoimmune diseases. Recent Pat Inflamm Allergy Drug Discov 2009, 3:177-187.
106. McIntosh L.M., Barnes J.L., Barnes V.L., McDonald J.R. Selective CCR2-targeted macrophage depletion ameliorates experimental mesangioproliferative glomerulonephritis. Clin Exp Immunol 2009, 155:295-303.
107. Douglass A., Wallace K., Parr R., Park J., Durward E., Broadbent I., et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 2008, 49:88-98.
108. Mirza R., DiPietro L.A., Koh T.J. Selective and specific macrophage ablation is detrimental to wound healing in mice. Am J Pathol 2009, 175:2454-2462.
109. Wada T., Yokoyama H., Su S.B., Mukaida N., Iwano M., Dohi K., et al. Monitoring urinary levels of monocyte chemotactic and activating factor reflects disease activity of lupus nephritis. Kidney Int 1996, 49:761-767.
110. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58:1492-1499.
111. Kitagawa K., Wada T., Furuichi K., Hashimoto H., Ishiwata Y., Asano M., et al. Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol 2004, 165:237-246.
112. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
113. Vielhauer V., Kulkarni O., Reichel C.A., Anders H.J. Targeting the recruitment of monocytes and macrophages in renal disease. Semin Nephrol 2010, 30:318-333.
114. Anders H.J., Vielhauer V., Frink M., Linde Y., Cohen C.D., Blattner S.M., et al. A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation. J Clin Invest 2002, 109:251-259.
115. Vielhauer V., Berning E., Eis V., Kretzler M., Segerer S., Strutz F., et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int 2004, 66:2264-2278.
116. Ninichuk V., Khandoga A.G., Segerer S., Loetscher P., Schlapbach A., Revesz L., et al. The role of interstitial macrophages in nephropathy of type 2 diabetic db/db mice. Am J Pathol 2007, 170:1267-1276.
117. Pixley F.J., Stanley E.R. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol 2004, 14:628-638.
118. Isbel N.M., Nikolic-Paterson D.J., Hill P.A., Dowling J., Atkins R.C. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol Dial Transplant 2001, 16:1638-1647.
119. Isbel N.M., Hill P.A., Foti R., Mu W., Hurst L.A., Stambe C., et al. Tubules are the major site of M-CSF production in experimental kidney disease: correlation with local macrophage proliferation. Kidney Int 2001, 60:614-625.
120. Le Meur Y., Tesch G.H., Hill P.A., Mu W., Foti R., Nikolic-Paterson D.J., et al. Macrophage accumulation at a site of renal inflammation is dependent on the M-CSF/c-fms pathway. J Leukoc Biol 2002, 72:530-537.
121. Ma F.Y., Ikezumi Y., Nikolic-Paterson D.J. Macrophage signalling pathways: a novel target in renal disease. Semin Nephrol 2010, 30:334-344.
122. Ma F.Y., Liu J., Kitching A.R., Manthey C.L., Nikolic-Paterson D.J. Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney. Am J Physiol Renal Physiol 2009, 296:F177-F185.
123. Ma F.Y., Sachchithananthan M., Flanc R.S., Nikolic-Paterson D.J. Mitogen activated protein kinases in renal fibrosis. Front Biosci (Schol Ed) 2009, 1:171-187.
124. Lim A.K., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Thomas M.C., Flavell R.A., et al. Role of MKK3-p38 MAPK signalling in the development of type 2 diabetes and renal injury in obese db/db mice. Diabetologia 2009, 52:347-358.
125. Han Y., Masaki T., Hurst L.A., Ikezumi Y., Trzaskos J.M., Atkins R.C., et al. Extracellular signal-regulated kinase-dependent interstitial macrophage proliferation in the obstructed mouse kidney. Nephrology (Carlton) 2008, 13:411-418.
126. Ferenbach D.A., Kluth D.C. Macrophage cell therapy in renal disease. Semin Nephrol 2010, 30:345-353.